Empiric treatment options in the management of complicated intra-abdominal infections.
Complicated intra-abdominal infections remain a major challenge for surgeons and internists because of their association with high morbidity and mortality. For optimal outcome, these infections require a combination of appropriate and timely surgical source control and adjunctive broad-spectrum antimicrobial therapy. This review discusses criteria for choosing empiric antimicrobial therapy, outlines available treatment options, and highlights new antimicrobial therapies for these infections.
Weigelt
John A
JA
Department of Surgery, Division of Trauma/Critical Care, Medical College of Wisconsin, Milwaukee, WI 53226, USA. jweigelt@mcw.edu
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D000077726:Doripenem; D024881:Drug Resistance, Bacterial; D013502:General Surgery; D006801:Humans; D007388:Internal Medicine; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010529:Peritoneal Cavity / Q000382:microbiology*; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D012307:Risk Factors; D012720:Severity of Illness Index; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D000077726:Doripenem; D008911:Minocycline